secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cencora, Inc. (COR)
CIK:        0001140859
Form:       8-K
Filed at:   2026-01-16T23:59:59+00:00
Accession:  0001104659-26-004524
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cencora secures $5.5B in financing for OneOncology acquisition; $4.5B bridge replaced
--------------------------------------------------------------------------------

- Revolving credit facility increased by $1.0B to $5.5B via amendment on Jan 12, 2026.
- Entered $1.5B term loan facility ($500M Tranche One, $1.0B Tranche Two) to fund acquisition.
- Entered $3.0B 364-day term loan facility to pay consideration and fees for acquisition.
- Existing $4.5B bridge financing automatically reduced to zero upon new facilities.
- Interest margins range from 75-125 bps over SOFR; leverage covenant max 4.00x with potential increase to 4.50x.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1140859/000110465926004524/0001104659-26-004524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1140859/000110465926004524/tm263332d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-004524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer